CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...

GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).

GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).

THURSDAY, Sept. 5, 2024 -- Lung function remains stable over three years after hematopoietic cell transplant (HCT) among patients with sickle cell...

Learn how low-intensity blood stem cell transplants improve lung function and offer new hope for adults with sickle cell disease.

The FDA accepts and grants priority review to SpringWorks' NDA for mirdametinib for treating neurofibromatosis type 1-associated plexiform...

Metronidazole is a standard treatment drug for Trichomoniasis; however, it has high breakthrough rate. Studies ongoing to change to alternate...

Sickle cell disease is an inherited red blood cell disorder that affects hemoglobin, the protein carrying oxygen through the body. In this...

GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.

Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy...